Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial

• Main Authors: Xingyu Zhou (Author), Xiaohong Wu (Author), Yong Cai (Author), Shouchun Cao (Author), Xiaoping Zhu (Author), Qiang Lv (Author), Huaigong Chen (Author), Leitai Shi (Author), Jia Li (Author), Xinjie Wang (Author), Yuhua Li (Author), Rong Zhou (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The large-scale production of a human diploid cell (HDC) vaccine (HDCV) for rabies is limited by several technical challenges. Kanghua Biological Products Co., Ltd., has successfully used microcarrier technology for the large-scale culture of HDCs in bioreactors to develop a lyophilized and purified...